首页 > 最新文献

Texas Heart Institute Journal最新文献

英文 中文
Patent Foramen Ovale-Related Hypoxemia After Bilateral Lung Transplant. 双侧肺移植后与卵相关的低氧血症。
IF 0.9 4区 医学 Pub Date : 2023-10-20 DOI: 10.14503/THIJ-23-8229
Lekhya Raavi, Pankaj Garg, Mohammad Alomari, Mostafa Ali, Ishaq Wadiwala, Magdy M El-Sayed Ahmed

A 64-year-old man with interstitial pulmonary fibrosis and a small patent foramen ovale with right-to-left shunting underwent bilateral lung transplant without closure of the patent foramen ovale. Postoperatively, the patient remained persistently hypoxemic with partial response to high-flow oxygen. Investigations revealed the presence of a large patent foramen ovale with right-to-left shunting on echocardiography and a shunt fraction of 21% on cardiac catheterization. Two months after the lung transplantation, primary surgical repair of the patent foramen ovale was performed with immediate improvement in oxygenation. Three years postoperatively, the patient remained oxygen independent.

一名患有间质性肺纤维化和小卵圆孔未闭(右向左分流)的64岁男子接受了双侧肺移植,但卵圆孔未闭合。术后,患者持续低氧血症,对高流量氧气有部分反应。研究显示,超声心动图显示存在大的卵圆孔未闭,从右向左分流,心导管插入术显示分流率为21%。肺移植两个月后,对卵圆孔未闭进行了初次手术修复,氧合立即改善。术后三年,患者仍保持吸氧状态。
{"title":"Patent Foramen Ovale-Related Hypoxemia After Bilateral Lung Transplant.","authors":"Lekhya Raavi, Pankaj Garg, Mohammad Alomari, Mostafa Ali, Ishaq Wadiwala, Magdy M El-Sayed Ahmed","doi":"10.14503/THIJ-23-8229","DOIUrl":"10.14503/THIJ-23-8229","url":null,"abstract":"<p><p>A 64-year-old man with interstitial pulmonary fibrosis and a small patent foramen ovale with right-to-left shunting underwent bilateral lung transplant without closure of the patent foramen ovale. Postoperatively, the patient remained persistently hypoxemic with partial response to high-flow oxygen. Investigations revealed the presence of a large patent foramen ovale with right-to-left shunting on echocardiography and a shunt fraction of 21% on cardiac catheterization. Two months after the lung transplantation, primary surgical repair of the patent foramen ovale was performed with immediate improvement in oxygenation. Three years postoperatively, the patient remained oxygen independent.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49693143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recovery of Lung Function After 149 Days on Extracorporeal Membrane Oxygenation for COVID-19. 体外膜氧合治疗COVID-19后149天肺功能恢复情况。
IF 0.9 4区 医学 Pub Date : 2023-10-20 DOI: 10.14503/THIJ-23-8132
Orlando R Suero, Sri Kartik Valluri, Mario H Farias-Kovac, Leo Simpson, Gabriel Loor, Diana M Guerra, Jose L Diaz-Gomez, Subhasis Chatterjee

This report highlights survival and the patient's perspective after prolonged venovenous extracorporeal membrane oxygenation (ECMO) for COVID-19-related respiratory failure. A 36-year-old man with COVID-19 presented with fever, anosmia, and hypoxia. After respiratory deterioration necessitating intubation and lung-protective ventilation, he was referred for ECMO. After 3 days of conventional venovenous ECMO, he required multiple creative cannulation configurations. Adequate sedation and recurrent bradycardia were persistent challenges. After 149 consecutive days of ECMO, he recovered native lung function and was weaned from mechanical ventilation. This represents the longest-duration ECMO support in a survivor of COVID-19 yet reported. Necessary strategies included unconventional cannulation and flexible anticoagulation.

本报告强调了COVID-19相关呼吸衰竭患者长时间静脉-静脉体外膜肺氧合(ECMO)后的生存率和患者的观点。一名患有新冠肺炎的36岁男子出现发烧、嗅觉缺失和缺氧。在呼吸系统恶化需要插管和肺部保护性通气后,他被转诊接受ECMO。经过3天的常规静脉-静脉ECMO,他需要多种创造性的插管配置。充分的镇静和复发性心动过缓是持续的挑战。在连续使用ECMO 149天后,他恢复了原有的肺功能,并停止了机械通气。这是迄今为止报道的新冠肺炎幸存者中持续时间最长的ECMO支持。必要的策略包括非常规插管和灵活的抗凝治疗。
{"title":"Recovery of Lung Function After 149 Days on Extracorporeal Membrane Oxygenation for COVID-19.","authors":"Orlando R Suero, Sri Kartik Valluri, Mario H Farias-Kovac, Leo Simpson, Gabriel Loor, Diana M Guerra, Jose L Diaz-Gomez, Subhasis Chatterjee","doi":"10.14503/THIJ-23-8132","DOIUrl":"10.14503/THIJ-23-8132","url":null,"abstract":"<p><p>This report highlights survival and the patient's perspective after prolonged venovenous extracorporeal membrane oxygenation (ECMO) for COVID-19-related respiratory failure. A 36-year-old man with COVID-19 presented with fever, anosmia, and hypoxia. After respiratory deterioration necessitating intubation and lung-protective ventilation, he was referred for ECMO. After 3 days of conventional venovenous ECMO, he required multiple creative cannulation configurations. Adequate sedation and recurrent bradycardia were persistent challenges. After 149 consecutive days of ECMO, he recovered native lung function and was weaned from mechanical ventilation. This represents the longest-duration ECMO support in a survivor of COVID-19 yet reported. Necessary strategies included unconventional cannulation and flexible anticoagulation.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Impact of Patient-Prosthesis Mismatch After Aortic Valve Replacement With a Mechanical or Biological Prosthesis. 机械或生物人工瓣膜置换术后患者人工瓣膜不匹配的临床影响。
IF 0.9 4区 医学 Pub Date : 2023-10-18 DOI: 10.14503/THIJ-22-8048
Milos Matkovic, Nemanja Aleksic, Ilija Bilbija, Ana Antic, Jelena Milin Lazovic, Marko Cubrilo, Aleksandar Milojevic, Igor Zivkovic, Svetozar Putnik

Background: Patient-prosthesis mismatch (PPM) may impair functional capacity and survival after aortic valve replacement. This study aimed to investigate the impact of PPM on long-term survival and quality of life after mechanical and biological aortic valve replacement.

Methods: This study included 595 consecutive patients who had undergone isolated aortic valve replacement. Patients were divided into 2 groups according to prosthesis type. The baseline and operative characteristics, survival rates, complications, and quality of life of the groups with and without PPM were compared for up to 6 years. The PPM calculation was performed using the effective orifice area value provided by the manufacturer divided by the patient's body surface area.

Results: The moderate to severe PPM rates were 69.8% and 3.7% after biological and mechanical prosthesis implantation, respectively. Mean survival for patients in the biological group who had PPM was statistically significantly shorter (50.2 months [95% CI, 45.2-55.3]) than for patients in the biological group without PPM (60.1 months [95% CI, 55.7-64.4]; P = .04). In the mechanical prosthesis group, there was no difference in mean survival between the subgroup with PPM (66.6 months [95% CI, 58.3-74.9]) and the subgroup without PPM (64.9 months [95% CI, 62.6-67.2]; P = .50). A quality-of-life questionnaire's scores did not differ between the groups.

Conclusion: Mismatch is common after biological valve implantation and statistically significantly affects long-term survival and quality of life. If the risk of PPM after implantation of a biological prosthesis is suspected, adopting strategies to avoid PPM at the time of surgery is warranted.

背景:患者假体不匹配(PPM)可能会损害主动脉瓣置换术后的功能能力和生存率。本研究旨在研究PPM对机械和生物主动脉瓣置换术后长期生存率和生活质量的影响。方法:本研究包括595例连续接受隔离主动脉瓣置换术的患者。根据假体类型将患者分为2组。比较有PPM组和无PPM组的基线和手术特征、生存率、并发症和生活质量长达6年。PPM计算使用制造商提供的有效孔口面积值除以患者体表面积。结果:生物和机械假体植入后,中重度PPM发生率分别为69.8%和3.7%。有PPM的生物组患者的平均生存期(50.2个月[95%CI,45.2-55.3])在统计学上显著短于无PPM的生物小组患者(60.1个月[95%CI,55.7-6.4];P=0.04),有PPM的亚组(66.6个月[95%CI,58.3-74.9])和无PPM的亚群(64.9个月[95%CI,62.6-67.2];P=.50)的平均生存率没有差异。生活质量问卷的得分在两组之间没有差异。结论:不匹配在生物瓣膜植入术后很常见,在统计学上显著影响远期生存率和生活质量。如果怀疑植入生物假体后存在PPM风险,则有必要在手术时采取避免PPM的策略。
{"title":"Clinical Impact of Patient-Prosthesis Mismatch After Aortic Valve Replacement With a Mechanical or Biological Prosthesis.","authors":"Milos Matkovic, Nemanja Aleksic, Ilija Bilbija, Ana Antic, Jelena Milin Lazovic, Marko Cubrilo, Aleksandar Milojevic, Igor Zivkovic, Svetozar Putnik","doi":"10.14503/THIJ-22-8048","DOIUrl":"10.14503/THIJ-22-8048","url":null,"abstract":"<p><strong>Background: </strong>Patient-prosthesis mismatch (PPM) may impair functional capacity and survival after aortic valve replacement. This study aimed to investigate the impact of PPM on long-term survival and quality of life after mechanical and biological aortic valve replacement.</p><p><strong>Methods: </strong>This study included 595 consecutive patients who had undergone isolated aortic valve replacement. Patients were divided into 2 groups according to prosthesis type. The baseline and operative characteristics, survival rates, complications, and quality of life of the groups with and without PPM were compared for up to 6 years. The PPM calculation was performed using the effective orifice area value provided by the manufacturer divided by the patient's body surface area.</p><p><strong>Results: </strong>The moderate to severe PPM rates were 69.8% and 3.7% after biological and mechanical prosthesis implantation, respectively. Mean survival for patients in the biological group who had PPM was statistically significantly shorter (50.2 months [95% CI, 45.2-55.3]) than for patients in the biological group without PPM (60.1 months [95% CI, 55.7-64.4]; P = .04). In the mechanical prosthesis group, there was no difference in mean survival between the subgroup with PPM (66.6 months [95% CI, 58.3-74.9]) and the subgroup without PPM (64.9 months [95% CI, 62.6-67.2]; P = .50). A quality-of-life questionnaire's scores did not differ between the groups.</p><p><strong>Conclusion: </strong>Mismatch is common after biological valve implantation and statistically significantly affects long-term survival and quality of life. If the risk of PPM after implantation of a biological prosthesis is suspected, adopting strategies to avoid PPM at the time of surgery is warranted.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49693141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory Pathways and Their Implications in Heart Failure With Preserved Ejection Fraction. 射血分数保留的心力衰竭的炎症途径及其意义。
IF 0.9 4区 医学 Pub Date : 2023-10-18 DOI: 10.14503/THIJ-23-8223
Matthew W Segar, Stephanie A Coulter
{"title":"Inflammatory Pathways and Their Implications in Heart Failure With Preserved Ejection Fraction.","authors":"Matthew W Segar, Stephanie A Coulter","doi":"10.14503/THIJ-23-8223","DOIUrl":"10.14503/THIJ-23-8223","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49693142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Science Is a Self-Correcting Discipline: Revisiting the Biological Potential of Adult Cardiac Progenitors. 科学是一门自我修正的学科:重新审视成年心脏祖细胞的生物学潜力。
IF 0.9 4区 医学 Pub Date : 2023-10-17 DOI: 10.14503/THIJ-23-8241
Daniele Torella, Eleonora Cianflone
{"title":"Science Is a Self-Correcting Discipline: Revisiting the Biological Potential of Adult Cardiac Progenitors.","authors":"Daniele Torella, Eleonora Cianflone","doi":"10.14503/THIJ-23-8241","DOIUrl":"10.14503/THIJ-23-8241","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Takotsubo Syndrome in Black Americans: Insights From the National Inpatient Sample. 美国黑人的Takotsubo综合征:来自全国住院患者样本的见解。
IF 0.9 4区 医学 Pub Date : 2023-10-17 DOI: 10.14503/THIJ-22-8055
Olga Vriz, Ali Hassan Mushtaq, Ahmed Nahid Elshaer, Abdullah Shaik, Irene Landi, Talal Alzahrani

Background: Data on race-related differences in the clinical outcomes of Takotsubo syndrome are limited, particularly for Black patients. This study aimed to assess whether race and sex may have an additional impact on the inpatient mortality of patients with Takotsubo syndrome.

Methods: A total of 4,628 patients from the United States' National Inpatient Sample from 2012 to 2016 were identified; propensity score analysis revealed a similar propensity score between Black patients (n = 2,314) and White patients (n = 2,314), which was used to balance observed covariates. Sex and age distributions were identical between the 2 groups. The groups were also similar in baseline characteristics, including cardiovascular risk factors. White patients were compared with Black patients on in-hospital outcomes and inpatient mortality. A logistic regression analysis was conducted to measure the difference in mortality based on race and sex.

Results: Compared with White patients, Black patients had a higher percentage of in-hospital complications, including cerebrovascular accidents (4.9% vs 2.5%, P ≤ .01), acute kidney injury (25% vs 19%, P ≤ .01); longer lengths of stay (8 vs 7 days, P ≤ .01); and higher inpatient mortality (6.1% vs 4.5%, P < .01). When analysis was conducted with race and sex combined, inpatient mortality was higher among Black men than among White women (odds ratio, 2.7 [95% CI, 1.80-3.95]; P ≤ .01).

Conclusion: This study showed that Black patients with Takotsubo syndrome have higher in-hospital complications and inpatient mortality rates. When race and sex were combined, inpatient mortality was significantly higher among Black men than among either White men and women or Black women.

背景:关于Takotsubo综合征临床结果种族相关差异的数据有限,尤其是黑人患者。本研究旨在评估种族和性别是否会对Takotsubo综合征患者的住院死亡率产生额外影响。方法:对2012年至2016年美国全国住院患者样本中的4628名患者进行鉴定;倾向得分分析显示,黑人患者(n=2314)和白人患者(n=231 4)之间的倾向得分相似,用于平衡观察到的协变量。两组之间的性别和年龄分布相同。两组的基线特征也相似,包括心血管风险因素。将白人患者和黑人患者的住院结果和住院死亡率进行比较。进行了逻辑回归分析,以衡量基于种族和性别的死亡率差异。结果:与白人患者相比,黑人患者的住院并发症比例更高,包括脑血管意外(4.9%vs 2.5%,P≤.01)、急性肾损伤(25%vs 19%,P≤0.01);停留时间较长(8天vs 7天,P≤.01);和更高的住院死亡率(6.1%vs 4.5%,P<0.01)。当将种族和性别相结合进行分析时,黑人男性的住院死亡率高于白人女性(优势比,2.7[95%CI,1.80-3.95];P≤.01)。结论:本研究表明,患有Takotsubo综合征的黑人患者有更高的院内并发症和住院死亡率。当种族和性别相结合时,黑人男性的住院死亡率明显高于白人男性和女性或黑人女性。
{"title":"Takotsubo Syndrome in Black Americans: Insights From the National Inpatient Sample.","authors":"Olga Vriz, Ali Hassan Mushtaq, Ahmed Nahid Elshaer, Abdullah Shaik, Irene Landi, Talal Alzahrani","doi":"10.14503/THIJ-22-8055","DOIUrl":"10.14503/THIJ-22-8055","url":null,"abstract":"<p><strong>Background: </strong>Data on race-related differences in the clinical outcomes of Takotsubo syndrome are limited, particularly for Black patients. This study aimed to assess whether race and sex may have an additional impact on the inpatient mortality of patients with Takotsubo syndrome.</p><p><strong>Methods: </strong>A total of 4,628 patients from the United States' National Inpatient Sample from 2012 to 2016 were identified; propensity score analysis revealed a similar propensity score between Black patients (n = 2,314) and White patients (n = 2,314), which was used to balance observed covariates. Sex and age distributions were identical between the 2 groups. The groups were also similar in baseline characteristics, including cardiovascular risk factors. White patients were compared with Black patients on in-hospital outcomes and inpatient mortality. A logistic regression analysis was conducted to measure the difference in mortality based on race and sex.</p><p><strong>Results: </strong>Compared with White patients, Black patients had a higher percentage of in-hospital complications, including cerebrovascular accidents (4.9% vs 2.5%, P ≤ .01), acute kidney injury (25% vs 19%, P ≤ .01); longer lengths of stay (8 vs 7 days, P ≤ .01); and higher inpatient mortality (6.1% vs 4.5%, P < .01). When analysis was conducted with race and sex combined, inpatient mortality was higher among Black men than among White women (odds ratio, 2.7 [95% CI, 1.80-3.95]; P ≤ .01).</p><p><strong>Conclusion: </strong>This study showed that Black patients with Takotsubo syndrome have higher in-hospital complications and inpatient mortality rates. When race and sex were combined, inpatient mortality was significantly higher among Black men than among either White men and women or Black women.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting Cell Senescence to Improve Cardiac Regeneration. 靶向细胞衰老以改善心脏再生。
IF 0.9 4区 医学 Pub Date : 2023-10-17 DOI: 10.14503/THIJ-23-8262
Georgina M Ellison-Hughes
phenotype (
{"title":"Targeting Cell Senescence to Improve Cardiac Regeneration.","authors":"Georgina M Ellison-Hughes","doi":"10.14503/THIJ-23-8262","DOIUrl":"10.14503/THIJ-23-8262","url":null,"abstract":"phenotype (","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of a Commercial Physical Activity Monitor in Longitudinal Tracking of Patients With Pulmonary Hypertension: A Pilot Study. 商业体育活动监测仪对肺动脉高压患者纵向跟踪的疗效:一项初步研究。
IF 0.9 4区 医学 Pub Date : 2023-10-17 DOI: 10.14503/THIJ-22-7866
Eliana Rosenzweig, Gerson Antonio Valencia Villeda, Sarah Crook, Fatima Koli, Erika B Rosenzweig, Usha S Krishnan

Background: Patients with pulmonary arterial hypertension have quality-of-life limitations, decreased exercise capacity, and poor prognosis if the condition is left untreated. Standard exercise testing is routinely performed to evaluate patients with pulmonary arterial hypertension but may be limited in its ability to monitor activity levels in daily living.

Objective: To evaluate the validity of the commercial Fitbit Charge HR as a tool to assess real-time exercise capacity as compared with standard exercise testing.

Methods: Ambulatory pediatric and adult patients were enrolled and given a Fitbit with instructions to continuously wear the device during waking hours. Patients underwent a 6-minute walk test, cardiopulmonary exercise test, and a 36-Item Short Form Health Survey on the day of enrollment and follow-up. Twenty-seven ambulatory patients with pulmonary arterial hypertension were enrolled, and 21 had sufficient data for analyses (median age, 25 years [range, 13-59 years]; 14 female participants).

Results: Daily steps measured by the Fitbit had a positive correlation with 6-minute walk distance (r = 0.72, P = .03) and an inverse trend with World Health Organization functional class. On the 36-Item Short Form Health Survey, 77% of patients reported improvement in vitality (P = .055). At follow-up, there was a strong correlation between number of steps recorded by Fitbit and role limitations because of physical problems (r = 0.88, P = .02) and weaker correlations with other quality-of-life markers.

Conclusion: The findings of this pilot study suggest activity monitors may have potential as a simple and novel method of assessing longitudinal exercise capacity and activity levels in patients with pulmonary hypertension. Further study in larger cohorts of patients is warranted to determine which accelerometer measures correlate best with outcomes.

背景:肺动脉高压患者的生活质量受到限制,运动能力下降,如果不治疗,预后不佳。标准运动测试通常用于评估肺动脉高压患者,但其监测日常生活活动水平的能力可能有限。目的:与标准运动测试相比,评估商业Fitbit Charge HR作为评估实时运动能力的工具的有效性。方法:对门诊儿科和成人患者进行登记,并给他们一个Fitbit,指示他们在醒着的时候继续佩戴该设备。患者在入组和随访当天接受了6分钟步行测试、心肺运动测试和36项简式健康调查。入选了27名肺动脉高压门诊患者,21名患者有足够的数据进行分析(中位年龄,25岁[范围,13-59岁];14名女性参与者)。结果:Fitbit测量的每日步数与6分钟步行距离呈正相关(r=0.72,P=.03),与世界卫生组织功能分类呈反比。在36项简式健康调查中,77%的患者报告活力有所改善(P=0.055)。在随访中,Fitbit记录的步数与因身体问题而造成的角色限制之间存在很强的相关性(r=0.88,P=0.02),与其他生活质量指标的相关性较弱。结论:这项初步研究的结果表明,活动监测仪可能是评估肺动脉高压患者纵向运动能力和活动水平的一种简单而新颖的方法。有必要在更大的患者队列中进行进一步研究,以确定哪些加速度计测量与结果最相关。
{"title":"Efficacy of a Commercial Physical Activity Monitor in Longitudinal Tracking of Patients With Pulmonary Hypertension: A Pilot Study.","authors":"Eliana Rosenzweig, Gerson Antonio Valencia Villeda, Sarah Crook, Fatima Koli, Erika B Rosenzweig, Usha S Krishnan","doi":"10.14503/THIJ-22-7866","DOIUrl":"10.14503/THIJ-22-7866","url":null,"abstract":"<p><strong>Background: </strong>Patients with pulmonary arterial hypertension have quality-of-life limitations, decreased exercise capacity, and poor prognosis if the condition is left untreated. Standard exercise testing is routinely performed to evaluate patients with pulmonary arterial hypertension but may be limited in its ability to monitor activity levels in daily living.</p><p><strong>Objective: </strong>To evaluate the validity of the commercial Fitbit Charge HR as a tool to assess real-time exercise capacity as compared with standard exercise testing.</p><p><strong>Methods: </strong>Ambulatory pediatric and adult patients were enrolled and given a Fitbit with instructions to continuously wear the device during waking hours. Patients underwent a 6-minute walk test, cardiopulmonary exercise test, and a 36-Item Short Form Health Survey on the day of enrollment and follow-up. Twenty-seven ambulatory patients with pulmonary arterial hypertension were enrolled, and 21 had sufficient data for analyses (median age, 25 years [range, 13-59 years]; 14 female participants).</p><p><strong>Results: </strong>Daily steps measured by the Fitbit had a positive correlation with 6-minute walk distance (r = 0.72, P = .03) and an inverse trend with World Health Organization functional class. On the 36-Item Short Form Health Survey, 77% of patients reported improvement in vitality (P = .055). At follow-up, there was a strong correlation between number of steps recorded by Fitbit and role limitations because of physical problems (r = 0.88, P = .02) and weaker correlations with other quality-of-life markers.</p><p><strong>Conclusion: </strong>The findings of this pilot study suggest activity monitors may have potential as a simple and novel method of assessing longitudinal exercise capacity and activity levels in patients with pulmonary hypertension. Further study in larger cohorts of patients is warranted to determine which accelerometer measures correlate best with outcomes.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hippo Pathway Knockdown Gene Therapy in the Heart. 心脏中的Hippo通路敲除基因治疗。
IF 0.9 4区 医学 Pub Date : 2023-10-17 DOI: 10.14503/THIJ-23-8272
Todd R Heallen, James F Martin
{"title":"Hippo Pathway Knockdown Gene Therapy in the Heart.","authors":"Todd R Heallen, James F Martin","doi":"10.14503/THIJ-23-8272","DOIUrl":"10.14503/THIJ-23-8272","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Biomarkers for Cardiovascular Disease. 心血管疾病的新生物标志物。
IF 0.9 4区 医学 Pub Date : 2023-10-16 DOI: 10.14503/THIJ-23-8178
Stephanie J Kim, Fernanda C P Mesquita, Camila Hochman-Mendez

Cardiovascular disease is the leading cause of death and disability worldwide. Early detection and treatment of cardiovascular disease are crucial for patient survival and long-term health. Despite advances in cardiovascular disease biomarkers, the prevalence of cardiovascular disease continues to increase worldwide as the global population ages. To address this problem, novel biomarkers that are more sensitive and specific to cardiovascular diseases must be developed and incorporated into clinical practice. Exosomes are promising biomarkers for cardiovascular disease. These small vesicles are produced and released into body fluids by all cells and carry specific information that can be correlated with disease progression. This article reviews the advantages and limitations of existing biomarkers for cardiovascular disease, such as cardiac troponin and cytokines, and discusses recent evidence suggesting the promise of exosomes as cardiovascular disease biomarkers.

心血管疾病是全世界死亡和致残的主要原因。心血管疾病的早期发现和治疗对患者的生存和长期健康至关重要。尽管心血管疾病生物标志物取得了进展,但随着全球人口老龄化,心血管疾病的患病率在全球范围内继续增加。为了解决这个问题,必须开发对心血管疾病更敏感和更特异的新型生物标志物,并将其纳入临床实践。外泌体是心血管疾病的有前景的生物标志物。这些小泡由所有细胞产生并释放到体液中,并携带与疾病进展相关的特定信息。本文综述了现有心血管疾病生物标志物的优势和局限性,如心肌肌钙蛋白和细胞因子,并讨论了最近的证据,表明外泌体有望成为心血管疾病的生物标志物。
{"title":"New Biomarkers for Cardiovascular Disease.","authors":"Stephanie J Kim, Fernanda C P Mesquita, Camila Hochman-Mendez","doi":"10.14503/THIJ-23-8178","DOIUrl":"10.14503/THIJ-23-8178","url":null,"abstract":"<p><p>Cardiovascular disease is the leading cause of death and disability worldwide. Early detection and treatment of cardiovascular disease are crucial for patient survival and long-term health. Despite advances in cardiovascular disease biomarkers, the prevalence of cardiovascular disease continues to increase worldwide as the global population ages. To address this problem, novel biomarkers that are more sensitive and specific to cardiovascular diseases must be developed and incorporated into clinical practice. Exosomes are promising biomarkers for cardiovascular disease. These small vesicles are produced and released into body fluids by all cells and carry specific information that can be correlated with disease progression. This article reviews the advantages and limitations of existing biomarkers for cardiovascular disease, such as cardiac troponin and cytokines, and discusses recent evidence suggesting the promise of exosomes as cardiovascular disease biomarkers.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41240025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Texas Heart Institute Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1